Home › Triple-Negative Breast Cancer › California › San Francisco
Pag-aaral pangklinika para sa Triple-Negative Breast Cancer sa San Francisco, CA
Isang pag-aaral para sa Triple-Negative Breast Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa San Francisco. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Nagre-recruitPhase 3
- UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016), San Francisco
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Nagre-recruitPhase 3
- Kaiser Permanente - San Francisco ( Site 0080), San Francisco
Intratumoral N17350 in Advanced Solid Tumors
Nagre-recruitPhase 1/2
- University of California, San Francisco, San Francisco
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Nagre-recruitPhase 3
- City of Hope (Duarte), San Francisco
- UCSF Medical Center, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Nagre-recruitPhase 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Nagre-recruitPhase 2
- University of California, San Francisco, San Francisco
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Nagre-recruitPhase 2
- University of California San Francisco (UCSF), San Francisco
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Nagre-recruitPhase 2
- University of California San Francisco, San Francisco
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- University of California, San Francisco, San Francisco
A Study of NX-1607 in Adults With Advanced Malignancies
Nagre-recruitPhase 1
- University of California, San Francisco, San Francisco
A Multicenter Cancer Biospecimen Collection Study
Nagre-recruitObservasyonal na pag-aaral
- Curebase, San Francisco
Pag-aaral para sa Triple-Negative Breast Cancer sa ibang lungsod
- Houston, TX42 pag-aaral
- New York City, NY31 pag-aaral
- Nashville, TN28 pag-aaral
- Los Angeles, CA27 pag-aaral
- Boston, MA26 pag-aaral
- San Antonio, TX23 pag-aaral
- St. Louis, MO21 pag-aaral
- Arlington, VA20 pag-aaral
- Atlanta, GA20 pag-aaral
- Dallas, TX18 pag-aaral
- Chicago, IL16 pag-aaral
- Columbus, OH16 pag-aaral
Iba pang pag-aaral sa San Francisco
- Kanser sa Prostate45 pag-aaral
- Kanser sa Suso43 pag-aaral
- Non-Small Cell Lung Cancer36 pag-aaral
- Kanser (lahat ng uri)35 pag-aaral
- Pagkabigo ng Puso29 pag-aaral
- Metastatic Cancer28 pag-aaral
- Kanser sa Baga22 pag-aaral
- Melanoma22 pag-aaral
- Kanser sa Pancreas20 pag-aaral
- Kanser sa Ovary19 pag-aaral
- Colorectal Cancer18 pag-aaral
- Sakit sa Puso at Ugat ng Dugo18 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.